Platinum Investment Management’s Denali Therapeutics DNLI Stock Holding History

Platinum Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-55,341	Closed	-$1.63M	–	149
2023 Q2	$1.63M	Hold	55,341	–	–	0.06%	86
2023 Q1	$1.28M	Hold	55,341	–	–	0.04%	95
2022 Q4	$1.54M	Buy	55,341 +4,370	+9%	+$130K	0.06%	90
2022 Q3	$1.56M	Hold	50,971	–	–	0.07%	85
2022 Q2	$1.5M	Hold	50,971	–	–	0.06%	94
2022 Q1	$1.64M	Hold	50,971	–	–	0.05%	90
2021 Q4	$2.27M	Buy	50,971 +20,180	+66%	+$956K	0.06%	92
2021 Q3	$1.55M	Hold	30,791	–	–	0.04%	109
2021 Q2	$2.42M	Hold	30,791	–	–	0.06%	87
2021 Q1	$1.76M	Hold	30,791	–	–	0.04%	93
2020 Q4	$2.58M	Sell	30,791 -40,002	-57%	-$2.42M	0.06%	80
2020 Q3	$2.54M	Hold	70,793	–	–	0.06%	71
2020 Q2	$1.71M	Hold	70,793	–	–	0.04%	92
2020 Q1	$1.24M	Buy	+70,793	New	+$1.48M	0.03%	93

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Platinum Investment Management's DNLI Position: Q3 2023 in Review

Platinum Investment Management sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 55,341 shares — an estimated $1.63M sold.

Platinum Investment Management first reported a position in DNLI in Q1 2020 and held it in 14 quarters. The position peaked at $2.58M in Q4 2020. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

Platinum Investment Management reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
Platinum Investment Management sold 55,341 Denali Therapeutics shares in Q3 2023, an estimated $1.63M.
Platinum Investment Management first reported a position in Denali Therapeutics in Q1 2020 and held it in 14 quarters.
Platinum Investment Management's Denali Therapeutics position peaked at $2.58M in Q4 2020.
194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Platinum Investment Management's 13F filing for Q3 2023, filed 3 Nov 2023.